Table 4.
Comparison of selected baseline characteristics of patients with and without decrease of trabecular bone score (TBS) (decrease in TBS equal to or exceeding the least significant change) after intravenous methylprednisolone therapy.
| Characteristic | Decrease of TBS 5/15 (33%) | No change of TBS 10/15 (66%) | P |
|---|---|---|---|
| Age (years), mean ± SD | 59.0 ± 13.8 | 50.9 ± 8.1 | 0.33 b |
| Women, n (%) | 5 (100%) | 8 (80%) | 0.52 a |
| Women after menopause, n (%) | 3 (60%) | 3 (30%) | 0.59 a |
| BMI (kg/m2), | 27.8 ± 6.3 | 27.4 ± 4.8 | 0.90 b |
| Smokers, n (%) | 2 (40%) | 4 (40%) | 1.00 a |
| TSH (µIU/mL), mean ± SD | 1.5 ± 2.0 | 1.9 ± 1.6 | 0.76 b |
| TRAb (IU/L), mean ± SD | 20.0 ± 17.4 | 10.3 ± 8.6 | 0.27 b |
| 25(OH)D (ng/mL), mean ± SD | 27.5 ± 7.0 | 34.7 ± 14.0 | 0.46 b |
| Osteopenia (T score -1.0 to >-2.5), n (%) | 2 (40%) | 2 (10%) | 0.56 a |
| Degraded or partially disturbed microarchitecture (TBS <1.31), n (%) | 1 (20%) | 4 (40%) | 0.60 a |
| Lumbar spine BMD (g/cm2), mean ± SD | 1.040 ± 0.1 | 1.061 ± 0.1 | 0.81 b |
a
Chi-squared Test;
b
Mann – Whitney U test.
BMD, bone mineral density; BMI, body mass index; TBS, trabecular bone score; TSH, thyroid-stimulating hormone; TRAb, TSH receptor antibodies; SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D.